Men researching alternatives to testosterone replacement therapy typically seek to address one of three clinical considerations: preserving fertility, avoiding a Schedule III controlled substance, or starting with a medical protocol that does not replace natural hormone production.
Clinical testosterone replacement therapy uses formulations approved by the U.S. Food and Drug Administration (FDA), including injectable esters and topical gels, to treat hypogonadism confirmed by two separate morning blood tests under Endocrine Society guidance. While TRT restores serum hormone concentrations directly, external testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis. This signaling suppression lowers sperm production while treatment continues.
Three main categories of alternatives exist for men seeking to improve symptoms or support hormone pathways:
- Prescription medications like enclomiphene stimulate your body's own testosterone production and preserve fertility without replacing the hormone directly.
- Over-the-counter testosterone boosters are widely available, but they lack the randomized trial evidence supporting clinical TRT.
- Peptide therapy stimulates your body's own hormone pathways to support energy, recovery, and sexual function without directly raising testosterone levels.
Evaluating these options begins with identifying the clinical cause of your hormone symptoms through comprehensive blood testing.
Enclomiphene for Natural Hormone Signaling
Enclomiphene is an oral selective estrogen receptor modulator (SERM) evaluated in men diagnosed with secondary or functional hypogonadism. Rather than introducing external testosterone into the bloodstream, enclomiphene blocks estrogen negative feedback at the hypothalamus and pituitary gland. This action stimulates the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), prompting the testes to produce endogenous testosterone.1 Because the medication maintains internal signaling through the HPG axis, it supports testosterone production without reducing sperm count.1
The regulatory status of enclomiphene differs from standard TRT. No enclomiphene product is approved by the U.S. Food and Drug Administration (FDA).2 The FDA proposed excluding enclomiphene citrate from the 503A Bulks List for pharmacy compounding. In June 2022, the Pharmacy Compounding Advisory Committee voted eight to four against including enclomiphene citrate, citing insufficient clinical efficacy evidence.2 As a result, enclomiphene is accessed through licensed compounding pharmacies rather than commercial retail channels.
Clinical trials comparing SERM therapy to standard testosterone administration provide measurable data on hormone outcomes. A 2025 systematic review and meta-analysis evaluated randomized controlled trials comparing SERM therapy (clomiphene and enclomiphene) to testosterone gel in men with hypogonadism.3 The researchers found no statistically significant difference in total testosterone concentrations between SERM therapy and testosterone gel. However, LH and FSH concentrations were higher in men receiving SERM therapy.3 Because the analysis pooled data from clomiphene and enclomiphene trials, these findings reflect class-level results rather than direct proof of equivalence between enclomiphene specifically and TRT.
Tolerability differences between SERM compounds were evaluated in a retrospective, single-center study following 66 patients who received clomiphene and subsequently switched to enclomiphene.4 Enclomiphene showed lower odds of adverse events compared to clomiphene, with an odds ratio of 0.18 and a 95% confidence interval of 0.07 to 0.44.4 Patients reported fewer instances of decreased libido, reduced energy, and mood changes while taking enclomiphene.4 The study authors noted that larger studies remain necessary to confirm long-term safety. A physician can assess these clinical trade-offs side by side, and our review of TRT vs enclomiphene provides a closer look at both treatments.
Over-the-Counter Testosterone Boosters
Over-the-counter testosterone supplements are sold across retail stores and online platforms without a prescription. Men frequently review these retail formulations as an initial step before consulting a medical provider.
The primary limitation of retail options centers on clinical substantiation. While over-the-counter testosterone boosters are widely available, they lack the randomized trial evidence supporting clinical TRT. Unlike prescription therapies evaluated in structured human trials, over-the-counter products are regulated as dietary supplements. Manufacturers do not need to prove clinical efficacy in treating hypogonadism prior to retail distribution.
Relying on retail supplements without diagnostic lab testing leaves the underlying cause of fatigue, low libido, or changes in body composition unaddressed. Symptoms of low testosterone require objective blood testing to differentiate between primary testicular failure, pituitary signaling dysfunction, and lifestyle factors. Men experiencing persistent symptoms require clinical diagnostics rather than retail supplement purchases.
Peptide Therapy for Pathway Support
Peptide therapy offers another non-replacement strategy for men managing changes in body composition, recovery, and sexual wellness. Rather than directly raising serum testosterone, peptide therapy stimulates your body's own hormone pathways to support energy, recovery, and sexual function, and because it works through those pathways rather than replacing testosterone directly, it does not suppress testicular function or shut down natural testosterone synthesis the way TRT does.
The regulatory environment surrounding peptide therapy requires careful physician oversight. Most peptides marketed for anti-aging or muscle building, including the growth-hormone-stimulating peptides used in clinical protocols, are not FDA-approved drugs. They are dispensed through specialized compounding pharmacies. The FDA has flagged certain bulk drug substances used in compounding because of limited human safety data and purity concerns.5
Because quality varies across unverified sources, obtaining peptides outside of medical supervision presents health risks. Working with a prescribing physician ensures peptides are sourced from accredited compounding facilities that verify purity, potency, and sterile handling under professional supervision.
Clinical Comparison Across Treatment Options
Selecting between testosterone therapy and alternative protocols requires weighing regulatory status, biological mechanisms, and reproductive plans.
| Treatment Option | Primary Mechanism | FDA Regulatory Status | Effect on Fertility |
|---|---|---|---|
| TRT | Replaces testosterone directly using exogenous hormones | Formulations are FDA-approved (Schedule III controlled substance) | Suppresses HPG axis and lowers sperm count during treatment |
| Enclomiphene | Stimulates pituitary LH and FSH to prompt testicular production | Not FDA-approved; prepared via compounding pharmacies | Preserves endogenous signaling and maintains sperm production |
| Peptide Therapy | Stimulates internal pathways for energy, recovery, and physical function | Most compounds are not FDA-approved; prepared via compounding | Does not suppress the HPG axis or diminish fertility |
| OTC Boosters | Variable dietary supplement ingredients | Not FDA-approved; regulated as dietary supplements | Not established in randomized trials |
TRT remains the established medical intervention for restoring testosterone concentrations in hypogonadal men, supported by FDA approvals for injectable esters and topical gels. However, the requirement for ongoing Schedule III administration and the suppression of natural spermatogenesis make it unsuitable for men who plan to conceive.
Enclomiphene provides a clinical mechanism to increase testosterone while preserving fertility, but lacks commercial FDA approval. Peptide therapy addresses recovery, energy, and sexual health through parallel endocrine pathways without altering gonadal hormone production. A physician evaluates your complete lab profile to determine which protocol matches your biology and long-term health priorities.
The Opt Take on TRT Alternatives
At Opt Health, care begins with diagnostic testing rather than an automatic prescription. We test more than 55 biomarkers at home or through a partner lab, analyzing total testosterone, free testosterone, LH, FSH, estradiol, metabolic health, and cardiovascular risk indicators.
An Opt Health physician reviews your complete panel during a one-on-one video consultation. Your physician determines whether your symptoms stem from primary testicular deficiency, secondary signaling failure, or metabolic stress. We evaluate your fertility plans directly alongside your lab results. Depending on your biomarkers and personal goals, your physician can prescribe TRT, enclomiphene, or targeted peptide therapies through accredited compounding pharmacies.
Care continues with follow-up blood panels and physician consultations scheduled every three to four months. We track your biomarker shifts over time, adjusting protocols as your lab results and clinical symptoms evolve.
Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop.
Frequently Asked Questions
Peptide therapy stimulates your body's own hormone pathways to support energy, recovery, and sexual function without directly raising testosterone levels. Over-the-counter supplements are also non-hormonal options, but they lack the randomized trial evidence supporting clinical TRT.
A meta-analysis of randomized controlled trials found no statistically significant difference in total testosterone between SERM therapy and testosterone gel, while LH and FSH were higher with SERMs.3 However, that analysis pooled clomiphene and enclomiphene trials together, so it does not confirm clinical equivalence for enclomiphene alone.
Over-the-counter testosterone boosters cannot replace clinical TRT because they lack the randomized controlled trial evidence confirming efficacy in treating hypogonadism. Prescription TRT uses FDA-approved formulations that directly restore testosterone levels under physician supervision.
References
- Earl JA, Kim ED. Enclomiphene citrate: A treatment that maintains fertility in men with secondary hypogonadism. Expert Rev Endocrinol Metab. 2019;14(3):157-165. https://pubmed.ncbi.nlm.nih.gov/31063005/
- U.S. Food and Drug Administration. Final Summary Minutes of the Pharmacy Compounding Advisory Committee Meeting, June 8, 2022. FDA Center for Drug Evaluation and Research. https://www.fda.gov/media/161293/download
- Hohl A, Chavez MP, Pasqualotto E, Ferreira ROM, et al. Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials. Arch Endocrinol Metab. 2025;69(5):e250093. https://pubmed.ncbi.nlm.nih.gov/41066380/
- Saffati G, Kassab J, Orozco Rendon D, Hinojosa-Gonzalez DE, et al. Safety and efficacy of enclomiphene and clomiphene for hypogonadal men. Transl Androl Urol. 2024;13(9):1984-1990. https://pubmed.ncbi.nlm.nih.gov/39434750/
- U.S. Food and Drug Administration. Certain Bulk Drug Substances that May Be Used in Compounding Under Section 503A. FDA Center for Drug Evaluation and Research. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.
This article is part of our guide to testosterone. See how physician-managed TRT works at Opt Health.
You might also like
Start Today
Your health, your terms. Discover how personalized care can transform not just the way you feel, but how you live.